China Conditionally Approves Fanregratinib in FGFR2 Cholangiocarcinoma
China’s National Medical Products Administration granted conditional approval to HUTCHMED’s fanregratinib, marketed as ATLED, for adults with advanced, metastatic or unresectable intrahepatic cholangiocarcinoma harboring FGFR2 fusion or rearrangement after prior systemic therapy. The approval…
